NCT02331472 is a clinical trial in Chronic Interstitial Cystitis, sponsored by Asan Medical Center.

Who is sponsoring NCT02331472?

NCT02331472 is sponsored by Asan Medical Center.

What condition does NCT02331472 study?

NCT02331472 studies Chronic Interstitial Cystitis.

Is NCT02331472 still recruiting?

NCT02331472 is currently completed. Last updated 5 July 2019.

Last reviewed 2019-07-05 · How we verify

NCT02331472

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy of Urine Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome (Pilot Study)

Completed Last updated 5 July 2019

What this trial tests

trial in Chronic Interstitial Cystitis in 80 participants. Completed in 14 January 2016.

Timeline

3 February 2015

Primary endpoint
14 January 2016

14 January 2016

Quick facts

Lead sponsor	Asan Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	80
Start date	3 February 2015
Primary completion	14 January 2016
Estimated completion	14 January 2016
Sites	2 locations across South Korea

Conditions studied

Chronic Interstitial Cystitis — all drugs for Chronic Interstitial Cystitis →

Sponsor

Asan Medical Center

Who can join

20 and older, any sex, with Chronic Interstitial Cystitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to evaluate the efficacy of urine biomarker in patients with interstitial cystitis/painful bladder syndrome

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Interstitial Cystitis

Currently open trials in the same condition.

NCT06299683 — Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment · NA · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02331472 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 5 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02331472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing